Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Cancer Research

• Publication date

  2014-11-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-14-1790PMID 25424847PMCID PMC4297523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-grade gliomas.

  2014cited by this paper
• Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.

  2014influential reference
• A vaccine targeting mutant IDH1 induces antitumour immunity

  2014cited by this paper
• Immune-Checkpoint Blockade and Active Immunotherapy for Glioma

  2013cited by this paper
• LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma

  2013cited by this paper
• Molecular pathogenesis of IDH mutations in gliomas

  2012cited by this paper
• Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

  2011cited by this paper
• Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.

  2011cited by this paper
• Do we need novel radiologic response criteria for brain tumor immunotherapy?

  2011cited by this paper
• Low-grade gliomas in adults.

  2011cited by this paper
• Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

  2011influential reference
• Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

  2011cited by this paper
• COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.

  2011cited by this paper
• Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners

  2010cited by this paper
• Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.

  2009cited by this paper
• IL-4 Suppresses Very Late Antigen-4 Expression Which is Required for Therapeutic Th1 T-cell Trafficking Into Tumors

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma1

  2008cited by this paper
• IL‐4 inhibits VLA‐4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit

  2008cited by this paper
• Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo1

  2008cited by this paper
• Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial.

  2008cited by this paper
• Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

  2007cited by this paper
• Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas

  2007cited by this paper
• Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors.

  2007cited by this paper
• Suppression of Antitumor Immunity by IL-10 and TGF-β-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells1

  2006cited by this paper
• Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

  2006influential reference
• A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma.

  2006influential reference
• Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein

  2006cited by this paper
• Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.

  2006cited by this paper
• Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions

  2005cited by this paper
• Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index

  2005cited by this paper
• EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.

  2005influential reference
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors

  2004influential reference
• Low-grade gliomas in adults

  2004influential reference
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

  2002cited by this paper
• Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma

  2002cited by this paper
• Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen, Interleukin 13 Receptor α2 Chain

  2002influential reference
• Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.

  2002cited by this paper
• Interleukin‐10 expressed at early tumour sites induces subsequent generation of CD4+ T‐regulatory cells and systemic collapse of antitumour immunity

  2001cited by this paper
• Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

  2001cited by this paper
• Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.

  2001influential reference
• Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.

  1999influential reference
• Predominance of a type 2 intratumoural immune response in fresh tumour‐infiltrating lymphocytes from human gliomas

  1996cited by this paper
• The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

  1995cited by this paper
• Selective expression of interleukin-10 gene within glioblastoma multiforme.

  1994cited by this paper
• Journal of Translational Medicine Toll like Receptor-3 Ligand Poly-iclc Promotes the Efficacy of Peripheral Vaccinations with Tumor Antigen-derived Peptide Epitopes in Murine Cns Tumor Models

  year unknowncited by this paper

• A cowpea mosaic virus adjuvant conjugated to liposomes loaded with tumor cell lysates as an ovarian cancer vaccine

  2025cites this paper
• Oligodendroglioma: Advances in Molecular Mechanisms and Immunotherapeutic Strategies

  2025cites this paper
• Enhanced Nano-Vaccine Utilizing Biomineralized Virus-like Particles for Efficient Glioblastoma Immunotherapy via the Nose-To-Brain Delivery Pathway.

  2025cites this paper
• Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements

  2024cites this paper
• The potential of mesenchymal stem cell coexpressing cytosine deaminase and secretory IL18-FC chimeric cytokine in suppressing glioblastoma recurrence.

  2024cites this paper
• A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives

  2024cites this paper
• Expression of Interleukin-13 Receptor Alpha 2 in Brainstem Gliomas

  2024cites this paper
• Advances in the treatment of IDH-mutant gliomas

  2024cites this paper
• Vaccines for cancer prevention: exploring opportunities and navigating challenges

  2024cites this paper
• Tenascin-C targeting strategies in cancer.

  2024cites this paper
• Synergistic effect of smac-mimetic and poly (I:C) on apoptosis of cholangiocarcinoma cells

  2023cites this paper
• Liquid biopsy-based identification of prognostic and immunotherapeutically relevant gene signatures in lower grade glioma

  2023cites this paper
• A co-formulated vaccine of irradiated cancer cells and cowpea mosaic virus improves ovarian cancer rejection.

  2023cites this paper
• Molecular subtypes based on centrosome-related genes can predict prognosis and therapeutic responsiveness in patients with low-grade gliomas

  2023cites this paper
• ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease

  2023cites this paper
• A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.

  2023cites this paper
• Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma

  2023influential citation
• Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures.

  2022cites this paper
• The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model

  2022cites this paper
• Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape

  2022cites this paper
• Host-pathogen protein-nucleic acid interactions: A comprehensive review

  2022cites this paper
• Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma

  2022cites this paper
• Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.

  2022cites this paper
• The immunology of low-grade gliomas.

  2022cites this paper
• Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments

  2021cites this paper
• Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas

  2021cites this paper
• Citrullinated Epitopes Identified on Tumour MHC Class II by Peptide Elution Stimulate Both Regulatory and Th1 Responses and Require Careful Selection for Optimal Anti-Tumour Responses

  2021cites this paper
• Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma

  2021influential citation
• Structural insights into the distinctive RNA recognition and therapeutic potentials of RIG‐I‐like receptors

  2021cites this paper
• Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis

  2021cites this paper
• A novel era of cancer/testis antigen in cancer immunotherapy.

  2021cites this paper
• Immunotherapy and Response Assessment in Malignant Glioma: Neuro-oncology Perspective.

  2020cites this paper
• Drug Conjugates for Targeting Eph Receptors in Glioblastoma

  2020cites this paper
• Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.

  2020cites this paper
• Immunotherapy and radiation for high-grade glioma: a narrative review

  2020cites this paper
• New horizons in adjuvants for vaccine development

  2020cites this paper
• Clinical Management of Diffuse Low-Grade Gliomas

  2020cites this paper
• Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia

  2020cites this paper
• T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment

  2020cites this paper
• Tumor antigens in glioma.

  2020cites this paper
• A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma

  2019cites this paper
• Dendritic Cells and Cancer: From Biology to Therapeutic Intervention

  2019cites this paper
• Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial

  2019cites this paper
• Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities

  2019cites this paper
• Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles

  2019cites this paper
• The role of dendritic cells in cancer.

  2019cites this paper
• Current strategies for vaccination in glioblastoma.

  2019cites this paper
• Immunotherapeutic effects of intratumoral nanoplexed poly I:C

  2019cites this paper
• Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

  2019cites this paper
• Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma

  2019cites this paper
• Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

  2019cites this paper
• Melanoma vaccines: clinical status and immune endpoints

  2019cites this paper
• Development of immune-modulatory RNAS to regulate RIG-I-like receptors mediated antiviral immune response for therapy and vaccination

  2018cites this paper
• Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma

  2018cites this paper
• Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.

  2018cites this paper
• Personalized cancer vaccines: adjuvants are important, too

  2018cites this paper
• Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma

  2018cites this paper
• Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

  2018cites this paper
• Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment

  2018cites this paper
• Immunotherapy for Brain Tumors

  2018cites this paper
• Receptor-Targeted Glial Brain Tumor Therapies

  2018cites this paper
• Trial watch: Peptide-based vaccines in anticancer therapy

  2018cites this paper
• The role of adjuvant-induced innate immune activation in shaping vaccine responses

  2018cites this paper
• Local Immunotherapies of Cancer

  2018cites this paper
• Immunotherapy of Gliomas

  2018cites this paper
• Federation of Neuro-Oncology Societies

  2018cites this paper
• Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence

  2017cites this paper
• Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants.

  2017cites this paper
• T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.

  2017cites this paper
• Emerging Therapies for Diffuse Low Grade Glioma

  2017cites this paper
• Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

  2017cites this paper
• Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies

  2017cites this paper
• Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

  2017cites this paper
• Overcoming immunosuppression in bone metastases.

  2017cites this paper
• History and current state of immunotherapy in glioma and brain metastasis

  2017cites this paper
• Vaccine-based immunotherapeutic approaches to gliomas and beyond

  2017cites this paper
• TLR Agonists as Adjuvants for Cancer Vaccines.

  2017cites this paper
• Peptide-Specific Vaccines

  2017cites this paper
• A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

  2017cites this paper
• Eph Receptor – Mediated Immune Cell

  2016cites this paper
• EVALUATION OF ALPHA-D-GLUCAN NANOPARTICLE AS A VACCINE ADJUVANT

  2016cites this paper
• Immunological boosting and personalization of oncolytic virotherapies for cancer treatment

  2016cites this paper
• Current status and future prospects of peptide-based cancer vaccines.

  2016cites this paper
• Prioritization schema for immunotherapy clinical trials in glioblastoma

  2016cites this paper
• IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.

  2016cites this paper
• Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

  2016cites this paper
• Pediatric low-grade gliomas: implications of the biologic era

  2016cites this paper
• Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential

  2016cites this paper
• CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).

  2016cites this paper
• Immunotherapy of Brain Cancer

  2016cites this paper
• Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas

  2016cites this paper
• Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?

  2016cites this paper
• Eph Receptor Tyrosine Kinases in Tumor Immunity.

  2016cites this paper
• Cellular immunotherapy for malignant gliomas

  2016cites this paper
• The Journal of Clinical Investigation

  2016cites this paper
• A Systemic Review of Clinical Trials on Dendritic-Cells Based VaccineAgainst Malignant Glioma

  2015cites this paper
• Insights on Peptide Vaccines in Cancer Immunotherapy

  2015cites this paper
• Vaccination strategies for neuro-oncology.

  2015cites this paper
• Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience

  2015cites this paper
• Immunotherapy for glioblastoma: concepts and challenges.

  2015cites this paper